Baxter International Inc.

BAX · NYSE · USD

PoliticiansInstitutionalInsiders

Current holders

Politician	Disclosed
Donald Trump R · EXECUTIVE	net −$64K – −$1K 3 disclosures · 1 bought / 2 sold · last Jul 23, 2026
Michael T. McCaul R · HOUSE · TX	$50K – $300K $121K – $401K today 3 filings · last Feb 17, 2026
Earl Blumenauer D · HOUSE · OR	$15K – $50K $11K – $37K today 1 filing · last Jul 9, 2024
Robert Bresnahan R · HOUSE · PA	$1K – $15K $816 – $12K today 1 filing · last May 15, 2025
Dean Phillips D · HOUSE · MN	−$41K – $57K −$12K – $17K today 7 filings · last Dec 18, 2020
William R. Keating D · HOUSE · MA	−$13K – $29K −$7K – $9K today 3 filings · last Dec 5, 2022
Debbie Wasserman Schultz D · HOUSE · FL	$1K – $15K $767 – $11K today 1 filing · last Nov 18, 2024
Raúl M. Grijalva D · HOUSE · AZ	−$14K – $14K −$11K – $9K today 2 filings · last Oct 15, 2015
Thomas MacArthur R · HOUSE · NJ	−$14K – $14K −$5K – $5K today 2 filings · last May 27, 2015
Lisa C. McClain R · HOUSE · MI	−$42K – $42K −$54K – $47K today 6 filings · last Oct 31, 2025

Recent transactions

Trades from Mar 6, 2025 – Jul 23, 2026

Politician	Type	Filed after	Amount
Donald Trump R · EXECUTIVE	Sell	61 days Jul 23, 2026 → Sep 22, 2026	≥$15K
Donald Trump R · EXECUTIVE	Buy	44 days May 18, 2026 → Jul 1, 2026	≥$1K
Donald Trump R · EXECUTIVE	Sell	47 days May 15, 2026 → Jul 1, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	13 days May 27, 2026 → Jun 9, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	25 days May 15, 2026 → Jun 9, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	39 days May 1, 2026 → Jun 9, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Sell	17 days Apr 24, 2026 → May 11, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Sell	28 days Apr 13, 2026 → May 11, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Sell	8 days Mar 30, 2026 → Apr 7, 2026	≥$1K
Michael T. McCaul R · HOUSE · TX-10	Buy	21 days Feb 17, 2026 → Mar 10, 2026	≥$100K

Congressional trading data provided by QuiverQuant

Institutional

Investors holding

722

13F shares

562.6M

Total invested

$12.0B

Ownership

109.2%

New positions

111

Closed positions

Increased positions

365

Reduced positions

197

Put/Call ratio

0.65

Holder	Reported	Shares	Value	Δ Qtr
BLACKROCK, INC.	8/7/2026	81.8M	$1.7B	+3.07%
PZENA INVESTMENT MANAGEMENT LLC	8/7/2026	65.3M	$1.4B	+1.19%
DODGE & COX	8/13/2026	58.4M	$1.2B	+1.98%
FMR LLC	8/13/2026	53.9M	$1.1B	+16.53%
VANGUARD CAPITAL MANAGEMENT LLC	8/13/2026	33.8M	$719.6M	+0.74%
VANGUARD PORTFOLIO MANAGEMENT LLC	8/13/2026	24.1M	$512.9M	+0.27%
STATE STREET CORP	9/22/2026	20.6M	$439.4M	+3.11%
GREENHAVEN ASSOCIATES INC	7/28/2026	14.3M	$304.6M	−0.16%
GEODE CAPITAL MANAGEMENT, LLC	8/12/2026	14.1M	$300.6M	+2.62%
INVESCO LTD.	8/14/2026	12.4M	$263.6M	−5.79%
UBS GROUP AG	8/13/2026	9.5M	$203.2M	+120.61%
FIRST PACIFIC ADVISORS, LP	8/14/2026	7.6M	$162.4M	+13.69%
GOLDMAN SACHS GROUP INC	8/14/2026	7.2M	$152.4M	+84.79%
EQUITY INVESTMENT CORP	8/7/2026	6.9M	$146.8M	+8.10%
MORGAN STANLEY	8/13/2026	6.4M	$135.6M	−13.45%
BANK OF AMERICA CORP /DE/	8/14/2026	6.2M	$133.0M	+1.16%
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO	8/12/2026	6.2M	$132.7M	+0.00%
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P.	8/14/2026	6M	$127.8M	—
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	8/14/2026	6M	$127.8M	+7.28%
DIMENSIONAL FUND ADVISORS LP	8/11/2026	5.6M	$119.7M	−5.39%
NORTHERN TRUST CORP	8/13/2026	4.9M	$103.7M	+11.89%
MARSHALL WACE, LLP	8/13/2026	4.9M	$103.6M	+114.29%
NORGES BANK	8/12/2026	4.1M	$88.4M	—
LSV ASSET MANAGEMENT	8/6/2026	3.9M	$83.5M	−3.60%
RWC ASSET MANAGEMENT LLP	7/27/2026	3.3M	$71.0M	+8.18%

Insider transactions

Insider	Type	Transacted	Price	Date
Rogers Terence John		0	—	Oct 1

Analyst consensus

Hold36 analysts

Bearish · 1 · Hold · 20 · Bullish · 15

Earnings history

	EPS	Estimate
Q3 2024	$0.80	$0.78	Beat
Q4 2024	$0.58	$0.53	Beat
Q1 2025	$0.55	$0.48	Beat
Q2 2025	$0.59	$0.60	Miss
Q3 2025	$0.69	$0.60	Beat
Q4 2025	$0.44	$0.53	Miss
Q1 2026	$0.36	$0.31	Beat
Q2 2026	$0.56	$0.37	Beat

Peers

Company overview

IPO dateOct 27, 1981

CEOAndrew Hider

Employees37,500

SectorHealthcare

IndustryMedical - Instruments & Supplies

CountryUS

ExchangeNew York Stock Exchange

Websitewww.baxter.com

Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.

Athenic provides research and information tools for educational purposes only and is not a registered investment adviser or broker-dealer. Nothing on this page is investment advice or a recommendation to buy or sell any security. Market data may be delayed. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal.